ITI Initiates Phase II Study of Insomnia Drug
Posted on: Friday, 21 December 2007, 12:00 CST
Intra-Cellular Therapies has initiated a Phase II clinical study with its drug candidate ITI-722, a highly potent 5HT2A antagonist for the treatment of sleep maintenance insomnia.
The Phase II program is a multi-center, randomized, double-blind placebo- controlled study in patients with sleep maintenance insomnia (SMI). The primary endpoint is an assessment of objective slow wave sleep using polysomnography (PSG). Secondary endpoints include other objective and subjective measures of SMI and sleep efficiency. Additionally, the study will make an assessment regarding next-day cognitive performance.
Sharon Mates, chairman and CEO of Intra-Cellular Therapies (ITI), said: "This drug candidate has therapeutic potential to treat SMI in the general population, and in other patient populations who have been underserved, particularly peri- and post-menopausal women, and in other disorders where insomnia is a problem."
Source: Datamonitor
Related Articles
- Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
- Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
- Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
- Benadryl Doesn't Help Young Children Sleep, Study Shows
- Institute Tireless in Sleep Studies
- Glaucoma eye pressure higher in sleep -study
- Newborn dolphins, killer whales never sleep -study
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients With Primary Sleep Maintenance Insomnia
- Researcher Plans Sunshine, Sleep Study
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Adults With Primary Sleep Maintenance Insomnia
 |
 |
User Comments (0)
RSS Feeds